Use of Choline Supplementation as Therapy for APOE4-Related Disorders

Technology

Apolipoprotein E (APOE4) is a key protein responsible for the transport and metabolism of lipids and cholesterol in the brain. Among the three major variants of the APOE gene—APOE2, APOE3, and APOE4—the APOE4 genotype is strongly associated with lipid dysregulation and related neurological and metabolic disorders, such as Alzheimer’s Disease (AD). The researchers have identified a novel molecular pathway specifically affected by the APOE4 genotype, leading to the disruption of lipid homeostasis. To address this, APOE4 carriers are administered with choline supplementation—typically at doses greater than 550 mg/day for at least three months. Choline, a direct precursor in the synthesis of phosphatidylcholine (PC), helps restore lipid balance by reducing lipid droplet accumulation in microglia and astrocytes, normalizing microglial activation, and decreasing amyloid β deposition. This mechanistic intervention improves PC metabolism and synaptic health, offering a targeted therapeutic strategy for APOE4-related disease pathologies.

Problem Addressed

APOE4 has been linked to various neurological and metabolic disorders including AD, Cerebral Amyloid Angiopathy, cardiovascular disease, atherosclerosis, and traumatic brain injury. While choline supplementation has previously been used in disease treatment contexts—including in AD—a connection between choline deficiency and the APOE4 specific genotype was not known prior to this invention. Therefore, choline treatment paradigms have largely not been stratified for APOE allele status and may fail to fully represent the beneficial effects of choline supplementation specific to APOE4 carriers. By uniting these two previously unconnected aspects of AD pathology and treatment, this technology establishes a mechanistic foundation for choline supplementation strategies to treat APOE4-related disorders.

Advantages

• Genotype-specific therapeutic targeting
• Mechanistic insight into APOE4-mediated lipid dysregulation
• Broad therapeutic applications across APOE4-related disorders